论文部分内容阅读
目的:观察急诊PCI(冠状动脉介入)术后患者四君子汤加减联合阿司匹林治疗对其预后的影响。方法:选取2014年3月~2015年2月我院心脏内科收治的86例急诊PCI术后患者为研究对象,随机数字表法分为两组各43例,对照组给予阿司匹林治疗,观察组给予四君子汤加减联合阿司匹林治疗,并进行为期一年的电话随访,观察治疗前、后两组心功能[左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]变化情况,并观察治疗前、后各指标[可溶性白介素2受体(s IL-2R)、超敏C-反应蛋白(hs CRP)、活化的T淋巴细胞(CD3+/HLA-DR+)]变化情况,同时观察两组治疗后再狭窄(RS)发生率。结果:治疗后观察组临床疗效88.37%较对照组69.77%显著高(P<0.05);治疗后两组LVESD、LVEDD分别均较治疗前显著减小,LVEF较治疗前显著增大,均差异显著(P<0.05),且治疗后观察组LVESD(48.92±7.11)mm、LVEDD(56.79±7.98)mm分别均较对照组减小显著,LVEF(45.36±4.39)%较对照组增大显著,均差异显著(P<0.05);治疗后观察组s IL-2R(620.13±452.21)U/ml、hs CRP(15.11±4.69)mg/L分别均较对照组降低显著,CD3+/HLA-DR+(10.89±4.39)%较对照组升高显著,均差异显著(P<0.05);治疗后观察组再狭窄发生率18.60%较对照组39.53%显著低(P<0.05)。结论:四君子汤加减联合阿司匹林对急诊PCI术后患者的治疗,可显著改善术后患者心功能,显著降低s IL-2R、hs CRP,显著升高CD3+/HLA-DR+,显著降低术后再狭窄发生率。
Objective: To observe the effect of Sijunzi Decoction combined with aspirin on the prognosis of patients after emergency PCI (coronary intervention). Methods: From March 2014 to February 2015, 86 patients undergoing emergency PCI in our hospital from January 2014 to February 2015 were enrolled in this study. The random number table was divided into two groups of 43 cases. The control group was given aspirin and the observation group was given Sijunzi Decoction plus aspirin treatment, and a one-year telephone follow-up, before and after treatment to observe cardiac function [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction LVEF) were observed before and after treatment. The levels of sIL-2R, hsCRP, CD3 + / HLA-DR + ] Changes, while observing the two groups after treatment of restenosis (RS) incidence. Results: After treatment, the clinical efficacy 88.37% in the observation group was significantly higher than 69.77% in the control group (P <0.05); LVESD and LVEDD in the two groups after treatment were significantly decreased compared with before treatment, LVEF significantly increased (P <0.05). After treatment, the LVESD (48.92 ± 7.11) mm and LVEDD (56.79 ± 7.98) mm in the observation group decreased significantly compared with the control group, and the LVEF (45.36 ± 4.39)% increased significantly (P <0.05). The levels of IL-2R (620.13 ± 452.21) U / ml and hs CRP (15.11 ± 4.69) mg / L in the observation group were significantly lower than those in the control group ± 4.39%) were significantly higher than those in control group (P <0.05). The incidence of restenosis in observation group was significantly lower than that in control group (18.60% vs 39.53%, P <0.05). Conclusion: Sijunzitang combined with aspirin can significantly improve the cardiac function, reduce the levels of sIL-2R and hs CRP, significantly increase the level of CD3 + / HLA-DR + and significantly reduce the postoperative restenosis Occurrence rate.